Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR4 | P46093 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 5/20 | 0.56 |
| ▸ | HRH2 | P25021 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034847 | 0.94 | HRH2 (0.61) | GPR4LTA4HHRH2HRH1KCNA5 | |
| SCHEMBL16825768 | 0.90 | HRH2 (0.56) | GPR4LTA4HHRH2HRH1KCNA5 | |
| SCHEMBL22609230 | 0.89 | LTA4H (0.58) | GPR4LTA4HDRD3PSMB1PSMB5 | |
| SCHEMBL15300688 | 0.89 | HRH2 (0.69) | HRH2HRH1RAB9AEPHX2DRD2 | |
| SCHEMBL25747712 | 0.86 | GPR4 (0.56) | GPR4LTA4HHRH2HRH1KCNA5 | |
| SCHEMBL22609266 | 0.85 | HRH2 (0.58) | GPR4LTA4HHRH2HRH1DRD3 | |
| SCHEMBL20075945 | 0.85 | HRH2 (0.52) | GPR4HRH2HRH1KCNA5DRD3 | |
| SCHEMBL14453585 | 0.83 | KCNA5 (0.62) | GPR4HRH2HRH1KCNA5DRD3 | |
| SCHEMBL19479118 | 0.83 | DRD3 (0.70) | HRH2HRH1KCNA5DRD3DRD2 | |
| SCHEMBL20423457 | 0.83 | DRD3 (0.55) | GPR4HRH2HRH1KCNA5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| EP-3731840-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | Orfan Biotech Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | PNPO, XDH, GLS | GPR4 2850/4885LTA4H 369/4885HRH2 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.